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Abstract. Background/Aim: Trastuzumab therapy, the
standard treatment for human epidermal growth factor
receptor type-2 (HER2)-positive breast cancer, is associated
with possible cardiotoxicity.  We set out to retrospectively
analyze the cardiac follow-up data of patients with breast
cancer receiving trastuzumab treatment. Patients and
Methods: The study involved 47 and 31 patients receiving
adjuvant or palliative chemotherapy plus trastuzumab,
respectively. Cardiovascular system assessments including
echocardiography were regularly performed.  Results: A
significant heart abnormality was detected in 44.7% of the
operable and 41.9% of metastatic cases. In the adjuvant
setting, left ventricular ejection fraction changes occurred
mostly during treatment and less frequently after its
completion (40.4% vs. 19.4%), while in the palliative setting,
35.5% and 40% in the first and the second year of therapy.
An asymptomatic atrial septum aneurysm was detected in
8.5% and 13% of the patients in the two groups. Conclusion:
Trastuzumab-related cardiotoxicity is mostly manifested in
an asymptomatic decrease in left ventricular ejection
fraction; hypertension, a high body mass index and left-sided
irradiation are its predictors.
Breast cancer is the most common cancer in women in
developed countries. The human epidermal growth factor
receptor type-2 (HER2)/neu protein is a 185-kDa
transmembrane cytoplasmic tyrosine kinase. Amplification of
the HER2 gene or overexpression of the HER2 protein occurs
in 10-34% of breast cancer cases (1), and is associated with
an adverse outcome (2). Trastuzumab (Herceptin®; Roche) is
a recombinant humanized monoclonal antibody that inhibits
tumor cell growth, differentiation and survival by binding with
high affinity to the extracellular domain, and blocking the
normal regulatory functions of the HER2 receptor (3).
The efficacy and safety of trastuzumab was first
demonstrated in patients with HER2-overexpressing
metastatic breast cancer (MBC) in different treatment lines,
and in combination with standard chemotherapeutic regimens
(4-7). In the adjuvant setting, the consistent outcome of
several large multi-center randomized trials (8-14) led to the
use of trastuzumab in HER2-positive breast cancer becoming
a new standard (3, 12).
Retrospective analysis of the pivotal phase II and III trials
revealed an increased incidence of cardiac dysfunction, usually
manifested as congestive heart failure (CHF), a symptomatic
or asymptomatic decrease of the left ventricular ejection
fraction (LVEF) or, rarely, cardiac arrhythmias or ischemic
heart disease (15). The incidence of cardiotoxicity in patients
with MBC was found to be highest in those receiving
concurrent trastuzumab and anthracyclines, but low when
trastuzumab was administered in combination with paclitaxel
or alone (16). The majority of these cases with a cardiac
dysfunction were symptomatic, but standard treatment for CHF
ameliorated the symptoms (17). In large studies in which the
use of trastuzumab in early breast cancer was evaluated, the
incidence of symptomatic cardiac dysfunction proved to be low
(18), even after a long follow-up or radiotherapy (RT) (13, 14).
Unlike the case with anthracyclines, trastuzumab-related
cardiac dysfunction constitutes an entity known as a type-2
chemotherapy-related cardiac dysfunction (CRCD), a
reversible abnormality with no structural changes in the
myocardium, not dose-dependent and which does not occur
in all patients (19-21). The mechanism of type-2 CRCD has
not been completely clarified and although several risk
factors for trastuzumab-induced cardiotoxicity have been
described, adverse cardiac events cannot be predicted (22).
With the aim of identifying risk factors for cardiac morbidity
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for our everyday practice, we set-out to perform a
retrospective study of cardiac follow-up data on patients with
breast cancer receiving trastuzumab in the adjuvant or
palliative setting.
Patients and Methods
All the procedures followed were in full accordance with the ethical
standards of the appropriate committees on human experimentation
(institutional and national) and with the Helsinki declaration.
The retrospective analysis included patients with histologically
confirmed, HER2-positive breast cancer who received adjuvant or
palliative trastuzumab therapy. All the clinical and pathological data
were extracted from the patient files.
The HER2 status was evaluated by immunohistochemical
staining or with fluorescence in situ hybridization (23).
Trastuzumab therapy. Patients received either adjuvant or
neoadjuvant chemotherapy with standard regimens (Table I).
Trastuzumab was given for 12 months at the standard dose (an 8
mg/kg loading dose and a 6 mg/kg sustaining dose at 3-week
intervals), usually after the chemotherapy, but in the case of the
sequential use of taxane monotherapy, it was co-administered with
either paclitaxel or docetaxel. After neoadjuvant chemotherapy, it
was always used as monotherapy. In metastatic cases, trastuzumab
was either co-administered with paclitaxel or was applied as
monotherapy following it, continued until disease progression.
Heart function surveillance. Heart function surveillance was carried
out in accordance with the internationally accepted guidelines (24).
Electrocardiography (ECG) and echocardiography were performed
prior to the initiation of trastuzumab therapy, at 3-month intervals
during the therapy, and at 6-month intervals after its termination;
this was carried out more frequently if any abnormality indicating a
deteriorating heart function was detected.
The presence of risk factors such as the age, body mass index
(BMI), baseline LVEF and echocardiography abnormalities,
hypertension, ischemic heart disease, diabetes mellitus, a smoking
history, the duration of trastuzumab therapy, the dose of
anthracycline chemotherapy and the administration of RT in cases of
left-sided breast cancer were extracted from the patient files.
Standard 2-dimensional transthoracic echocardiography was
performed by two experienced cardiologists using a standard
ultrasound machine (Toshiba PowerVision 8000 with a 2.0-3.8 MHz
transducer; Toshiba, Tustin, CA, USA). The LV dimensions and
volume parameters were obtained from standard parasternal and
apical 4-chamber views. The LVEF was calculated by the modified
Simpson's method, according to the guidelines of the American
Society of Echocardiography (24).
Study end-points. The reduction of LVEF by an absolute value of
10% or more from the baseline or its decrease below the level of
50% indicated a significant abnormality. The development of other
heart changes or heart failure was additionally analyzed. The
discontinuation of trastuzumab therapy was decided on an individual
basis, in accordance with the guidelines (25, 26). 
Statistical analysis. Data are reported as mean±SE or median values.
Comparison of the incidence of abnormal LVEF changes between
groups was carried out with the χ2 test or Fisher’s exact test. The
difference between the mean LVEF changes during the first and the
second year was analyzed with the paired samples t-test. SPSS 20.0
for Windows (SPSS Inc., Chicago, IL, USA) was used to perform
the analysis. A p-value of less than 0.05 was considered significant.
Results
Adjuvant trastuzumab therapy. Between September 2006 and
April 2012, 47 patients received adjuvant trastuzumab
therapy; the median (range) duration of follow-up was 12 (3-
36) months. The mean age (±SE) at diagnosis was 53.0±1.7
years. The tumor characteristics are shown in Table II. Two-
thirds of the neoplasms were poorly-differentiated and about
three-quarters of them were hormone receptor-negative. The
average (±SE) number of chemotherapy cycles that the
patients received before or during trastuzumab treatment was
5.62±0.27. Most patients completed the anthracycline-based
chemotherapy, 18 patients (38.3%) received concomitant
taxane and trastuzumab treatment, while 17 of those with left-
sided breast cancer received RT (Table III). At least one of
the patient-related risk factors for cardiovascular morbidity
was present in 68% of the cases (Table IV).
Echocardiography findings are included in Table V. A total
of 42 out of 47 patients completed a 1-year course of
trastuzumab therapy, while in five cases, trastuzumab
treatment was stopped after a mean duration of 5.2 (2.6-7)
months (in four cases due to disease progression and in one
due to a deterioration of cardiac function). The mean (±SE)
duration of trastuzumab therapy was 10.8±0.4 months, with
a median value of 11.9 months. The LVEF was normal at
baseline in all cases, but decreased by 10% or more in 21 out
of the 47 patients (44.7%). In 7/47 (14.9%) cases, these were
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Table I. The chemotherapeutic regimens applied in patients receiving
adjuvant trastuzumab treatment.
Chemotherapeutic Number of patients receiving 
regimen adjuvant trastuzumab treatment
CMF 7
CEF 10
AC-paclitaxel 14
AC-docetaxel 6
TAC 1
CMF-docetaxel 3
TEX 3
EC 1
Docetaxel-epirubicin 1
Paclitaxel-carboplatin 1
CMF=cyclophosphamide, methotrexate, 5-fluorouracil, CEF=
cyclophosphamide, epirubicin, 5-fluorouracil, AC=adriamycin, cytoxan,
TAC=taxotere, Adriamycin, cyclophosphamide, TEX=taxotere,
epirubicin, Xeloda, EC=epirubicin, cyclophosphamide.
merely isolated accidental findings during the treatment or
the follow-up period. Abnormal LVEF changes occurred in
19/47 (40.4%) and 7/36 (19.4%) patients in the first and the
second year, respectively. Among those who exhibited an
LVEF decrease of 10% or more, the mean (±SE) changes
were 10.58±1.82% (n=19) and 11.79±1.29% (n=7) in the
first and the second year, respectively. None of the patients
presented an LVEF <50% or symptoms of CHF. Four
patients (8.5%) developed atrial septum aneurysm during the
treatment or the follow-up period.
The presence of hypertension favored LVEF decrease by
10% or more (27.0% among those with hypertension vs.
12.4% among those without hypertension, p=0.004).
Likewise, LVEF decrease was associated with the earlier
delivery of left-sided RT (27.2% among those who received
RT vs. 15.2% among those who did not, p=0.023). No
statistically significant difference was found with regard to
the presence of diabetes or ischemic heart disease; however,
the numbers of such cases were low. With the median BMI
taken as threshold, patients with a BMI >26.6 kg/m2
demonstrated a higher incidence of abnormal LVEF changes
than that for patients with a BMI less than this, at 28.0% vs.
10.5% (p=0.001). No association was found between
abnormal LVEF reduction and treatment with anthracycline-
based chemotherapy or its dose. An abnormal LVEF change
during the first year correlated significantly with the presence
of hypertension and BMI, but not with left-sided RT, while
in the second (follow-up) year, only the association with left-
sided RT remained significant (Table VI).
Palliative trastuzumab therapy. Between June 2003 and
February 2012, 31 patients with MBC received chemotherapy
and trastuzumab in the palliative setting, 25 patients in the first-
line setting, and six in the second-line. Among them, nine
patients were maintained on trastuzumab, while 12 received
another oncological therapy throughout observation time. The
median duration of follow-up was 12 (3-36) months. The mean
age (±SE) of the patients was 54.7±2.2 years. Most of the
carcinomas were poorly differentiated, and hormone receptor-
negative (data not shown). The patients received an average
(±SE) of 7.59±0.87 chemotherapy cycles before or during
trastuzumab therapy; 12/31 patients (38.7%) were treated with
anthracycline-based chemotherapy before trastuzumab, while 27
patients (87.1%) received concomitant taxane and trastuzumab
therapy, and 11 patients left-sided RT (Table III). The mean
(±SE) duration of trastuzumab therapy was 27.6±7.1 months. In
five cases, trastuzumab monotherapy is ongoing.
Cardiovascular co-morbidities and risk factors were
present in 80% of the patients (Table IV).
The initial mean (±SE) LVEF was 66.2±1.1%; a cardiac
wall dysfunction was revealed in 5/31 patients (16.1%);
mitral valve regurgitation and tricuspid valve insufficiency
of grade 1 or 2 were the most common cardiac abnormalities
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Table II. Tumor characteristics in the patient population treated with
adjuvant, and neoadjuvant chemotherapy and adjuvant trastuzumab.
Tumor characteristics Patients (N=47)
N %
Histological type Invasive ductal carcinoma 46 97.9
Invasive lobular carcinoma 1 2.1
Grade 1 2 4.3
2 16 34.0
3 29 61.7
ER Negative (≤10%) 33 70.2
Positive (>10%) 14 29.8
PR Negative (≤10%) 36 76.6
Positive (>10%) 11 23.4
(y)pT (y)pT1 (≤20 mm) 29 61.7
(y)pT2 (>20 mm) 18 38.3
(y)pN (y)pN0 20 42.5
(y)pN1-2 27 57.5
Distribution
Unifocal 42 89.4
Multifocal 5 10.6
N=Number, ER=estrogen receptor, PR=progesterone receptor,
(y)pT=pathological tumor stage (after neoadjuvant treatment),
(y)pN=pathological lymph node stage (after neoadjuvant treatment).
Table III. Selected oncological therapies in the patient population
treated with trastuzumab in the adjuvant and palliative settings.
Previous/concomitant Patients receiving Patients receiving 
oncological therapy adjuvant palliative 
trastuzumab trastuzumab
treatment (N=47) treatment (N=31)
N % N %
Anthracycline chemotherapy 41 87.2 12 38.7
before trastuzumab therapy
Irradiated left-sided 17 36.2 11 35.5
breast cancer cases
Whole breast 8 17.0 5 16.1
Chest wall 9 19.1 6 19.4
Regional lymph nodes 9 19.1 9 29.0
Tumor bed boost 8 17.0 3 9.7
Endocrine therapy during 14 29.8 0 0.0
trastuzumab monotherapy
N=Number.
(83.9% and 45.2%, respectively), while an aortic valve
abnormality was reported in three patients (9.7%) (Table V).
In the overall population, 31/133 (23.3%) follow-up
echocardiographic tests showed an abnormal LVEF change.
The mean (±SE) decrease in the LVEF was 7.85±2.11%. The
development of an abnormal LVEF was observed at least
once in 13/31 (41.9%) patients: in 11/31 (35.5%), in the first
year of therapy and in 6/15 (40%), during the second year.
However, in 4/31 (12.9%) cases this was merely an isolated
accidental finding. The mean (±SE) decrease in the LVEF in
the first year in these 11 patients was 8.7±2.3%. For the six
patients who showed abnormal LVEF changes in the second
year only, the mean (±SE) decrease was 8.1±2.9%. None of
the patients developed symptomatic CHF. Three of the
patients had an atrial septum aneurysm, while one patient
exhibited pericardial fluid during the treatment.
More abnormal LVEF change was detected in patients with
than in those without hypertension (Table VII). Likewise,
there was a difference in the second year among those who
had received RT and those who had not (Table VII). No
difference was found concerning the presence of diabetes or
ischemic heart disease, although the numbers of such cases
were low. No association was detected between the incidence
of abnormal LVEF findings and BMI, treatment with or the
dose of anthracyclines, the lines or cycles of previous
chemotherapies, nor the cumulative dose of trastuzumab.
Cardiac dysfunction detected during the second year was
related to previous left-sided RT (Table VII).
Discussion
In our study, the incidence of asymptomatic cardiac
dysfunction categorized as significant was higher than
reported in large clinical trials (9-11, 27-35). None of our
patients, however, developed symptomatic CHF, and
approximately one-third of the cases in both groups exhibited
merely an isolated accidental 'significant' LVEF decrease.
The differences between our data and the published results
may stem from the relatively high proportion of patients with
risk factors for cardiovascular morbidity in our study. The
data from the different trials are also not fully comparable as
the assessment criteria, the definitions of cardiotoxicity and
the testing methods sometimes differ somewhat; nonetheless,
our methods did not differ in any fundamental way from
those in the literature (9, 10, 29, 36).
Cardiac abnormalities not related to pumping function
during trastuzumab therapy are under-reported. In our study,
an asymptomatic atrial septum aneurysm was detected in
8.5% of the cases in the adjuvant group, and in 13.0% in the
palliative group. Piotrowski et al. detected rare asymptomatic
left and right bundle branch blocks and other ECG
abnormalities (29). Olin et al. described newly-developed T-
wave inversions (37). The most clearly established risk factors
of trastuzumab-related cardiac events are the additive effect
of concurrent trastuzumab and anthracycline treatment,
previous anthracycline exposure and the cumulative dose of
anthracyclines received (16). Trastuzumab seems to change
the tertiary structure of the cardiac contractile apparatus
reversibly by inhibiting the HER2 receptors of
cardiomyocytes, and to lead to progressive mycocardial cell
apoptosis and destruction (38). This potentiates the adverse
effects of anthracyclines, i.e. the irreversible apoptosis of
myocytes induced by reactive oxygen species (22). Hence,
trastuzumab is administered following anthracycline
treatment. Heavy alcohol abuse (39), co-existing diabetes (40)
and older age (11, 32, 36), overweight and obesity,
hypertension (11, 36), RT (41) or genetic factors (22) were
suggested as predictors of trastuzumab-induced cardiac
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Table IV. Patient-related risk factors for cardiac morbidity in patients
with operable and metastatic breast cancer.
Patient-related risk Patients receiving Patients receiving 
factors for adjuvant trastuzumab palliative trastuzumab
cardiac morbidity treatment (N=47) treatment (N=31)
n % n %
Hypertension 23 48.9 19 61.3
Diabetes mellitus 6 12.8 3 9.7
Ischemic heart disease 3 3.4 1 3.2
Smoking 15 31.9 4 11.0
Median BMI (kg/m2) 26.6 29.5
≥Median 24 51.1 16 51.6
<Median 23 48.9 15 48.4
N=Number, BMI=Body Mass index, kg=kilogram, m2=quadratmeter.
Table V. Heart function parameters at baseline in patients receiving
adjuvant/palliative trastuzumab treatment.
Heart function parameter Population treated Population treated
at baseline with trastuzumab with trastuzumab 
in the adjuvant in the palliative 
setting (N=47) setting (N=31)
LVEF (mean±SE, %) 67.4±0.9 66.2±1.1
LVEF (median, %) 67.0 66.0
Wall dysfunction (N, %) 0 (0.0) 5 (16.1)
Mitral insufficiency (N, %) 20 (42.6) 26 (83.9)
Tricuspidal insufficiency (N, %) 14 (29.8) 14 (45.2)
Aortic valve abnormality (N %) 2 (4.3) 3 (9.7)
Pulmonary valve abnormality 2 (4.3) 0 (0.0)
(N, %)
N=Number, SE=standard error.
adverse effects. In our study, among patients receiving
adjuvant trastuzumab therapy, hypertension and high BMI
proved to be significant risk factors during the first year, as
did left-sided RT during the second year of observation. In
the adjuvant setting, no association was found between
trastuzumab-related cardiotoxicity and diabetes mellitus,
ischemic heart disease or the use or dose of anthracyclines.
In the metastatic group, only left-sided RT was a significant
risk factor during the second year of treatment.
Since trastuzumab-related cardiotoxicity is progressive and
initially asymptomatic, regular cardiac monitoring (using
multiple-gated acquisition scans or echocardiography) is
essential; the discontinuation of trastuzumab therapy and
specific therapy are justified in rare cases (24, 25). Besides
imaging methods, the measurement of plasma markers, such
as N-terminal pro-B-type natriuretic peptide as a marker of
myocardial strain, troponin-I as a sign of cardiac cell apoptosis
and necrosis (42) or high-sensitivity C-reactive protein (43),
may be used for the early detection of a cardiac dysfunction.
The limitations of our study include the small size of the
population included and the short follow-up period. 
In conclusion, given the substantial survival benefits of
trastuzumab therapy that have been recorded in both early
and MBC, the risk of cardiac complications (among which
an LVEF decrease during trastuzumab treatment is the most
common) can generally be justified. Our findings suggest
that trastuzumab-related cardiac dysfunction is manageable,
and largely reversible; it does not exclude patients from
further treatment with trastuzumab. All patients should be
evaluated for their cardiovascular status and risk factors for
type-2 CRCD prior to the initiation of trastuzumab treatment,
and cardiac surveillance should be routinely performed
during treatment with trastuzumab.
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